New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation, Challenging Industry Assumptions

Rhea-AI Summary

Omada Health (Nasdaq: OMDA) has released groundbreaking analysis challenging common assumptions about weight regain after GLP-1 medication discontinuation. The study of 816 members showed that 63% of participants maintained or continued losing weight 12 months after stopping GLP-1 medications, with only a 0.8% average weight change compared to typical 11-12% weight gain seen in clinical trials.

The analysis tracked outcomes at 6, 9, and 12 months post-discontinuation, demonstrating consistent weight maintenance throughout the year. Omada has supported over 100,000 members taking GLP-1 medications through their GLP-1 Care Track program, which provides behavioral support, dedicated care teams, connected devices, and an AI-enhanced digital experience.

Positive

• None.

Negative

• Rising costs of GLP-1 medications remain a challenge for employers

Insights

Healthcare Technology Analyst

Omada's data showing long-term weight maintenance post-GLP-1 discontinuation could significantly strengthen its value proposition in the crowded weight management market.

Omada Health's retrospective analysis demonstrates a striking divergence from clinical trial outcomes regarding weight maintenance after GLP-1 discontinuation. While clinical trials typically show 11-12% weight regain within a year of stopping GLP-1 medications, Omada's members experienced just 0.8% average weight change 12 months after discontinuation, with 63% maintaining or continuing to lose weight.

This data represents a potential paradigm shift in how we view GLP-1 medications' long-term effectiveness. The key differentiator appears to be Omada's comprehensive support system — behavioral coaching, dedicated care teams, connected devices, and AI-enhanced digital experiences — which provides the scaffolding needed for sustainable lifestyle changes.

For enterprise buyers facing escalating GLP-1 costs (which can exceed $1,000 monthly per patient), these findings position Omada as a value multiplier. Their platform potentially transforms GLP-1 medications from an ongoing expense into a time-limited intervention with sustainable results when paired with their digital health platform.

The market implications are substantial. With Omada supporting over 100,000 members taking GLP-1 medications, they've established significant scale in this rapidly expanding market. Their claims-based methodology using objective pharmacy data strengthens the credibility of these findings compared to self-reported outcomes.

What's particularly noteworthy is the consistency of results across timeframes (0.03% weight change at 6 months, 0.6% at 9 months, 0.8% at 12 months), suggesting that the critical post-discontinuation period can be effectively managed with proper support, potentially reducing the need for indefinite medication use.

Pharmaceutical Market Strategist

This data represents a significant advancement in understanding the GLP-1 ecosystem beyond medication alone. The analysis of 816 members reveals that comprehensive behavioral support can fundamentally alter the post-discontinuation trajectory compared to stand-alone pharmaceutical interventions.

The pharmaceutical industry has been grappling with the challenge of post-GLP-1 weight regain. Clinical trials for medications like semaglutide and tirzepatide have consistently shown substantial weight regain (11-12%) after discontinuation. This creates a perceived dependency model where ongoing medication use appears necessary for maintaining results.

Omada's findings disrupt this narrative by demonstrating that with proper support systems, GLP-1s could potentially function as temporary interventions rather than lifelong therapies. This has enormous implications for formulary decision-makers who are struggling with the budgetary impact of these medications.

The timing is particularly relevant as Mercer's recent survey indicates mounting pressure on employers to manage rising GLP-1 costs. Omada's approach offers a potential solution to the sustainability question that has plagued the GLP-1 market expansion.

The emphasis on muscle mass maintenance through activity guidance addresses a known limitation of GLP-1 therapy—that weight loss can include muscle loss without proper exercise protocols. This holistic approach suggests Omada understands the physiological nuances of GLP-1-assisted weight loss.

For pharmaceutical manufacturers, this data suggests potential partnership opportunities where medication and digital therapeutics could be bundled, potentially extending the total addressable market by making GLP-1 therapy more economically viable for payers and employers through improved long-term outcomes and potentially shorter treatment durations.

Analysis shows Omada members maintained weight, with minimal (0.8%) average weight change, one year after discontinuing GLP-1s for weight loss,1 suggesting the impact of continued lifestyle support from Omada

SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released results from a real-world analysis that showed 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s,¹ challenging widespread assumptions of inevitable post-medication weight regain. Since the GLP-1 Care Track launched, Omada has supported more than 100,000 members taking GLP-1 medications.

The retrospective analysis included 816 members in Omada’s GLP-1 Care Track and examined GLP-1 discontinuation and subsequent weight change at 6, 9, and 12 months.¹ At one year post-discontinuation members showed just 0.8% average weight change,¹ compared to 11-12% weight gain typically seen in clinical trials^2-3 where participants do not always have access to wraparound lifestyle support after they stop the medication.³ Omada’s analysis demonstrated participants largely experienced weight maintenance consistently throughout the year, with 0.03% average weight change at 6 months and 0.6% average weight change at 9 months,¹ suggesting the sustained impact of lifestyle support at this critical moment in their GLP-1 journey.

"As employers face mounting pressure to manage the rising costs of GLP-1s,⁴ these findings demonstrate how Omada’s program can help prevent wasted healthcare dollars and protect the investment in these expensive medications," said Wei-Li Shao, President, Omada Health. "We believe that GLP-1 success includes both weight loss and weight maintenance. These findings show that proper support can help members maintain weight loss long after they decide along with their provider to discontinue GLP-1s,¹ delivering lasting value to members and customers."

The analysis used claims-based methodology to track outcomes of members without diabetes enrolled in Omada’s GLP-1 Care Track at 6, 9, and 12 months post-discontinuation.¹ Omada offers behavioral support through dedicated care teams alongside connected devices and an AI-enhanced digital experience. Omada's program emphasizes the importance of maintaining muscle mass in members’ GLP-1 journeys, through activity and movement guidance for a holistic approach to weight health.

"While our previous research showed promising short-term results after GLP-1 discontinuation,⁵ this analysis strengthens those findings by using objective pharmacy claims data and demonstrating that success can be sustained in the long-term,¹" said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research at Omada Health. "As we see an increase in GLP-1 use,⁶ it's crucial that we understand how to support members at all phases of their weight health journey, including helping members maintain weight after discontinuing GLP-1s."

This study was completed as part of the Omada Insights Lab ANSWERS (Analyzing Success of Weight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada’s behavior change weight health programs. Learn more about Omada Health’s approach to GLP-1 medications and coverage here.

Omada Health
Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 30 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.

The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work^®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.

Great Place to Work^® is the registered trademark of the Great Place to Work Institute and is used under license.

Contacts
Rose Ramseth
press@omadahealth.com

Citations

1. Chang H, Devaraj SM, Naqvi JB, Napoleone J, Linke S. Weight maintenance is possible after GLP-1s—with the right support. Omada Health. Published September 8, 2025. Accessed September 8, 2025. https://resourcecenter.omadahealth.com/white-papers/weight-maintenance-is-possible-after-glp-1s-with-the-right-support.
2. Aronne, L.J., Sattar, N., Horn, D.B., et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
3. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
4. Mercer. Survey on health & benefit strategies for 2026 [PDF]. Mercer. Published July 2025. Accessed August 14, 2025. https://www.mercer.com/assets/us/en_us/shared-assets/local/attachments/pdf-2025-us-survey-on-health-and-benefit-strategies-for-2026.pdf.
5. Naqvi JB, Chang H, Berthoumieux A, Linke S, Napoleone J. Maintaining weight loss after GLP-1s: outcomes of a 16-week analysis. Omada Health. Published January 2025. Accessed August 11, 2025. https://resourcecenter.omadahealth.com/latest-content/omada-health-maintaining-weight-loss-after-glp-1s.
6. Mahase E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024;386:q1645. Published 2024 Jul 23. doi:10.1136/bmj.q1645

FAQ

What were the results of Omada Health's GLP-1 discontinuation study in 2025?

The study showed that 63% of members maintained or continued losing weight 12 months after stopping GLP-1 medications, with only a 0.8% average weight change, compared to typical 11-12% weight gain in clinical trials.

How many members has Omada's GLP-1 Care Track program supported?

Omada Health has supported more than 100,000 members taking GLP-1 medications through their GLP-1 Care Track program.

What is the average weight change for Omada members after stopping GLP-1 medications?

Omada members showed just 0.8% average weight change after 12 months, with 0.03% at 6 months and 0.6% at 9 months post-discontinuation.

How does Omada Health support members taking GLP-1 medications?

Omada provides behavioral support through dedicated care teams, connected devices, an AI-enhanced digital experience, and guidance on maintaining muscle mass through activity and movement.

How many participants were included in Omada's GLP-1 discontinuation analysis?

The retrospective analysis included 816 members in Omada's GLP-1 Care Track program, examining discontinuation and weight change at 6, 9, and 12 months.